Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase

Marco Colamonici, Gavin T. Blyth, Diana Saleiro, Amy Szilard, Meghan Bliss‐Moreau, Francis J. Giles, Jessica K. Altman, Elspeth M. Beauchamp, Leonidas C. Platanias

Oncotarget · 2015 · 18 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

// Marco Colamonici 1,2 , Gavin Blyth 1,2 , Diana Saleiro 1,2 , Amy Szilard 1,2 , Meghan Bliss-Moreau 1 , Francis J. Giles 1,2 , Jessica K. Altman 1,2,3 , Elspeth M. Beauchamp 1,2,3 and Leonidas C. Platanias 1,2,3 1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 2 Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 3 Division of Hematology-Oncology, Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL, USA Correspondence to: Leonidas C. Platanias, email: // Keywords : AML, mTOR signaling, PI3 kinase Received : January 01, 2015 Accepted : February 03, 2015 Published : March 10, 2015 Abstract The mammalian target of rapamycin (mTOR) and phosphoinositide-3-kinase (PI3K) pathways are often aberrantly activated in acute myeloid leukemia (AML) and play critical roles in proliferation and survival of leukemia cells. We provide evidence that simultaneous targeting of mTOR complexes with the catalytic mTOR inhibitor OSI-027 and of the p110α subunit of PI3K with the specific inhibitor BYL-719 results in efficient suppression of effector pathways and enhanced induction of apoptosis of leukemia cells. Importantly, such a combined targeting approach results in enhanced suppression of primitive leukemic progenitors from patients with AML. Taken together, these findings raise the possibility of combination treatments of mTOR and p110α inhibitors as a unique approach to enhance responses in refractory AML.

References

29